Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

The Effects and Mechanisms of Traditional Chinese Medicine and Extracts on Stem Cells and the Application of Stem Cells to Treat Disease: A Review.

Fang Y., Yu X., Feng Z., Qin F., Zheng Z., Zhu Y.

Clinical Trial on Diabetic Foot, Stroke Research, Chronic Inflammation, Immune Modulation, published in Curr Pharm Des (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Curr Pharm Des (2026)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
41832681
DOI
10.2174/0113816128436713251216113058

Abstract (original English)

This review examines the synergistic effects and mechanisms of Traditional Chinese Medicine (TCM) and its extracts on mesenchymal stem cells (MSCs), with a focus on enhancing MSC proliferation, differentiation, and immunomodulation for therapeutic applications. A comprehensive analysis of studies from the past five years was conducted, evaluating interactions between TCM/extracts and MSC types (bone marrow-, adipose-, and umbilical cord-derived MSCs) through molecular pathways (e.g., PI3K/Akt, Wnt/β- catenin, TGF-β/Smad) and microRNA regulation. In vitro, in vivo, and clinical trial data were synthesized. TCM and extracts significantly upregulated osteogenic/adipogenic differentiation in bone marrow mesenchymal stem cells via miR-335-5p/PTEN and Runx2 pathways, enhanced the viability of adipose-derived mesenchymal stem cells under oxidative stress via Sirt1/Akt activation, and improved the immunomodulation of umbilical cord mesenchymal stem cells by increasing anti-inflammatory factors (HGF, PGE2). Combined MSC-TCM therapies accelerated diabetic ulcer healing (via the miR-146A-NF-κB axis), reduced liver fibrosis (via miR-19b-3p), and mitigated stroke/arthritis symptoms. TCM synergizes with MSCs through multipathway crosstalk and miRNA regulation, amplifying therapeutic efficacy in degenerative, inflammatory, and ischemic diseases. Clinical translation requires standardized TCM

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research